On June 8, WuXi AppTec (02359.HK) fell 3.13% in regular trading, trading at 120.7 HKD/share, with trading volume of 170 million HKD.

On the institutional front, Morgan Stanley has continued to reduce its long position in WuXi AppTec H shares, with data showing its holding ratio declined from 5.09% to 4.43% as of June 2. This follows a more aggressive reduction from 7.72% to 4.27% on May 21, with foreign selling pressure still reverberating through the market. Additionally, the pharmaceutical sector faces multiple policy headwinds including tighter centralized procurement regulations and stricter medical insurance catalog adjustment rules, further suppressing valuation recovery momentum.

Within the Life Sciences Tools and Services sector, broad-based weakness persisted. Among individual stocks, WUXI BIO down 5.74%, INSILICO down 6.53%, GENSCRIPT BIO down 4.41%, WUXI XDC down 4.29%, XTALPI down 3.47%. Despite the company continuing to ramp up H-share buybacks, short-term selling pressure continues to weigh on share price performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)